The growing spectrum of neurotoxicities related to targeted cancer therapies can present a challenge for radiologists. In this
AJR Conversation, Neuroradiology Imaging Senior Editor Carlos Zamora, MD, PhD, speaks with Alvand Hasankhani, MD, about his team's recently published
article addressing the critical role of neuroimaging in detecting and differentiating neurotoxicity syndromes associated with common and emerging cancer therapies.
